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grade 2 or greater were 6.8% and 8.1%; and for gastrointestinal toxicities were 2.7% and 2%. We have found only a statistically
signiﬁcant difference in univariate analysis in rate of DFS with Swift (1.7%) vs tomography (7%).
Conclusions. In patients with PC, the treatment with EBRT and boost with HDR-BT allows deliver high BED with excellent results
and minimal toxicity.
http://dx.doi.org/10.1016/j.rpor.2013.03.809
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Objective. The International Diabetes Federation (IDF) estimated that around 20–25% of the adult population of the world has
metabolic syndrome (MetS). The patients (pts) with prostate cancer (PC) treated with androgen deprivation therapy (ADT), have
been reported to have higher prevalence of MetS. The objective of the study was to assess, the prevalence of MetS in patients
with PC who have received or will receive radiation therapy (RT) with radical intention and ADT.
Materials and methods. Multicenter prospective observational cross-sectional study of patients with PC who have received or will
receive RT with radical intention and ADT (6, 12–18, ≥24 months, and a control group without ADT), with the main primary
objective to analyze the prevalence of MetS in these pts. The presence of MetS was deﬁned according to the updated National
Cholesterol Education Program’s Adult Treatment Panel III by the presence of 3 or more of the following risk factors: (1) waist
circumference≥102 cm (European Cardiovascular Societies), (2) fasting blood sugar≥100mg/dL or previously diagnosed type
2 diabetes, (3) serum triglyceride level≥150mg/dL or pharmacological treatment for it, (4) systolic blood pressure≥130mm
Hg or diastolic blood pressure≥85mm Hg or previously diagnosed hypertension, and (5) high-density lipoprotein (cHDL) choles-
terol < 40 mg/dL. The study was approved by the Clinical Research Ethics Committee and the patient signed the informed consent
form.
Results. From November 2011 to October 2012, 256 pts were included in the study (50 pts without ADT, 55 pts with 6 months of
hormonal therapy, 91 pts in the group of 12–18 months and 60 pts in the group of ≥24 months ADT), and according to the above
criteria, 118 pts (46%) had MetS and are the object of our study. Median age was 72 years old (range 56-86). The prevalence of
MetS was 19.5% in patients without ADT, 20.3% in patients that received ADT for 6 months, 35.6% in pts treated for 12–18 months
with ADT and 24.6% in pts that received >24 months of hormonal therapy. The majority of pts had no family history of diabetes
mellitus, hypertension or dislipidemia.
Conclusion. According to our results patients with prostate cancer treated with androgen deprivation therapy for 12–18 months
present a higher prevalence of metabolic syndrome than patients treated with shorter or longer periods of hormonal treatment
and the general population.
http://dx.doi.org/10.1016/j.rpor.2013.03.810
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Purpose/objectives. Ki67 is a proliferation marker that provides an accurate estimate of growth fraction and outcome for patients
with prostate cancer. Expression of ERG (androgen dependent due to TMPRSS2-ERG fusion), are present in more than 50% of
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prostate cancer. The aim of this study is to determine the signiﬁcance of Ki-67 and ERG as a biomarker of patient outcome for
prostate cancer patients treated with radiotherapy.
Methods and materials. Pretreatment archival prostate biopsy tumor tissue was available from 339 stage T1–T4 prostate cancer
patients treatedwith external beam radiotherapy alone or in combinationwith androgendeprivation therapy (ADT) between 2003
and 2005. All patientswere diagnosed by needle biopsy andnone of themhad evidence ofmetastasis. Parafﬁn-embedded prostate
cancer tissue was available in 88/339 patients. Immunohistochemical staining of Ki-67 was used to determine the proliferation
index in each case. The Ki-67 was expressed as a percentage (<3 vs ≥3) of immunoreactive tumor cells to the total counted tumor
cells. ERG-EP11 monoclonal antibody was used to determine the presence of ERG protein. A positive reaction was considered
if the tumor cells showed a nuclear staining to ERG-EP11 antibody. Factors associated to failure, survival and progression were
analysed. Estimates of survival were determined using Kaplan–Meier methods. Unadjusted and adjusted hazard ratios were
calculated using the Cox regression model.
Results. Mean age was 70 years (range 56–84). T1–T2 stage 276 patients (81.5%), T3 61 patients (18%). Initial PSA (ng/ml) was <20,
279 patients (82.4%) and >20, 60 patients (17.6%). Forty-nine percent of patients had Gleason score≥7. Median radiation dose
to prostate was 74Gy. Whole pelvic irradiation was administered in 44%, and 75% received ADT. Expression of Ki-67≥3% was
observed in 64/82 patients (78%) and for ERG+ in 54/82 patients (66%) for the analyzed cohort. Intermediate (Ki-67≥3%, 13/20
pts, 65%, and ERG+, 14/20 pts, 70%), and high-risk (Ki-67≥3%, 45/53 pts, 85%, and ERG+, 35/53 pts, 66%) groups were the highest
expression observed (p<0.05). With a median follow-up of 7.28 years (range 1.4–15 years), the 10-year OS for Ki-67<3 vs Ki-67≥3%
was 89% and 87%, and 93% and 85% for ERG− vs ERG+. The 10-year BRFS for Ki-67<3 vs Ki-67≥3% was 100% and 73% (p 0.06), and
87% and 77% for ERG− vs ERG+. On univariate analysis (for entire cohort, 339 pts), initial psa (p 0.01), Gleason (p 0.001), and nadir
psa post-RT (p 0.001) were signiﬁcantly associated with biochemical failure. Ki-67≥3% was associated with a trend biochemical
failure (p 0.063). Estimates of survival and Cox regression model for 88/339 pts will be presented.
Conclusions. Expression of Ki-67≥3% and ERG+ obtained from pretreatment prostate cancer biopsies could be used as predictor
biomarkers of advanced stages, failure and survival after treatment with radiotherapy.
http://dx.doi.org/10.1016/j.rpor.2013.03.811
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Introduction. The intensity-modulated radiotherapy (IMRT) for prostate cancer permits further dose escalation and appears to be
less toxic compared to three-dimensional conformal radiotherapy (3D-CRT).
Objectives. To report the incidence of treatment-related toxicity after IMRT for prostate cancer.
Methods. Between January 2009 and December 2011, 79 patients with prostate cancer were treated with IMRT with doses ranging
from76 to 80Gy in 64patientswith stagesT1–T4prostate cancer and66–76Gy in 15patientswith a recurrence after prostatectomy.
The median follow-up was 20.95 months (6.1–39.6). Gastrointestinal (GI) and genitourinary (GU) posttreatment toxicities were
graded according to the RTOG Acute and Late Radiation Morbidity Scoring Criteria/Schema. Sexual toxicity was graded according
to theNational Cancer Institute’s CommonTerminology Criteria for Adverse Events (CTC 4.0).We evaluated the toxicity presented
during radiotherapy=0 months (0m), at 3 months (3m) and 6 months (6m) after completion of therapy (Acute Toxicity). Finally,
we evaluated the toxicity from 6 months of completing treatment to the last follow-up date (Late Toxicity).
Results. Grade≥2 toxicities of non-operated patients: Acute GU toxicity: 0m: 33.3%; 3m: 3.2%; 6m: 1.6%. Acute GI toxicity: 0m:
1.6%; 3m: 0%; 6m: 0%. Late GU toxicity: 1.6%. Late GI toxicity: 0%. Late sexual toxicity: 31%. Grade≥2 toxicities of operated
patients: Acute GU toxicity: 0m: 13.3%; 3m: 0%; 6m: 0%. Acute GI toxicity: 0m: 0%; 3m: 0%; 6m: 0%. Late GU toxicity: 7.1%. Late
GI toxicity: 0%. Late sexual toxicity was: 100%.
Conclusions. IMRT was feasible and sure, with low rates of serious acute toxicity and without any late grade 3–4 genitourinary or
gastrointestinal toxicity despite the delivery of high radiation dose levels. Many non-operated patients preserved erection long
term. More patients and longer follow-up are needed to conﬁrm our results.
http://dx.doi.org/10.1016/j.rpor.2013.03.812
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Introduction. Acute grade 3 toxicity is uncommon during stereotactic body radiation therapy (SBRT) for low-risk prostate cancer
(PCa) using robotic radiosurgery (Katz, 2010; Freeman, 2011).
Purpose. Single-institution single-arm prospective study in low-intermediate PCa. Endpoint: To assess acute toxicity (to
exclude>5% men have grade3 GU or any grade3 GI).
